Literature DB >> 18425328

Detection of a hypersialylated beta1 integrin endogenously expressed in the human astrocytoma cell line A172.

Petr Bartik1, Anne Maglott, Gustav Entlicher, Dietmar Vestweber, Ken Takeda, Sophie Martin, Monique Dontenwill.   

Abstract

Gliomas are the most common deadly brain tumors. Human cerebral tumors express high level of alpha5beta1 integrins. As a potential new target, alpha5beta1 was investigated here in two human astrocytoma cell lines, A172 and U87MG. We found that a hypersialylated beta1 integrin was endogenously expressed in A172 cells. It forms heterodimers with alpha5 subunits, localizes at the cell membrane and allows adhesion to fibronectin. This form of beta1 integrin was only recognized by the 9EG7 anti-beta1 antibody and appeared devoid of other specific antibody epitopes (12G10, TS2/16 and mAb13 shown here to be N-glycosylation sensitive). Overexpression of the beta1 integrin subunit in A172 cells not only increased the hypersialylated form but also led to the appearance of a non-hypersialylated beta1 form also addressed to the cell surface. Compared to wild-type A172 cells, beta1-A172 cells showed increased adhesion to fibronectin and decreased sensitivity to SJ749, a non-peptidic alpha5beta1 antagonist. In addition, beta1-A172 cells exhibited increased matrix dependence for normal cell cycling. Collectively, the data add new evidence for the role of beta1 glycosylation/sialylation in the regulation of integrin functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425328

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  Galectin-1 sensitizes carcinoma cells to anoikis via the fibronectin receptor α5β1-integrin.

Authors:  H Sanchez-Ruderisch; K M Detjen; M Welzel; S André; C Fischer; H-J Gabius; S Rosewicz
Journal:  Cell Death Differ       Date:  2010-11-26       Impact factor: 15.828

2.  An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family.

Authors:  Céline Cegarra; Béatrice Cameron; Catarina Chaves; Tarik Dabdoubi; Tuan-Minh Do; Bruno Genêt; Valérie Roudières; Yi Shi; Patricia Tchepikoff; Dominique Lesuisse
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

Review 3.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

4.  Structural and functional characterization of NanU, a novel high-affinity sialic acid-inducible binding protein of oral and gut-dwelling Bacteroidetes species.

Authors:  Chatchawal Phansopa; Sumita Roy; John B Rafferty; C W Ian Douglas; Jagroop Pandhal; Phillip C Wright; David J Kelly; Graham P Stafford
Journal:  Biochem J       Date:  2014-03-15       Impact factor: 3.857

5.  Sialidase NEU1 suppresses progression of human bladder cancer cells by inhibiting fibronectin-integrin α5β1 interaction and Akt signaling pathway.

Authors:  Xiaoman Zhou; Yanhong Zhai; Changmei Liu; Ganglong Yang; Jia Guo; Guang Li; Chengwen Sun; Xiaowei Qi; Xiang Li; Feng Guan
Journal:  Cell Commun Signal       Date:  2020-03-12       Impact factor: 5.712

6.  The Solute Carrier MFSD1 Decreases the Activation Status of β1 Integrin and Thus Tumor Metastasis.

Authors:  Marko Roblek; Julia Bicher; Merel van Gogh; Attila György; Rita Seeböck; Bozena Szulc; Markus Damme; Mariusz Olczak; Lubor Borsig; Daria E Siekhaus
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 7.  Galectins and gliomas.

Authors:  Marie Le Mercier; Shannon Fortin; Véronique Mathieu; Robert Kiss; Florence Lefranc
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

8.  Integrins and p53 pathways in glioblastoma resistance to temozolomide.

Authors:  Sophie Martin; Hana Janouskova; Monique Dontenwill
Journal:  Front Oncol       Date:  2012-10-31       Impact factor: 6.244

Review 9.  Gangliosides as Biomarkers of Human Brain Diseases: Trends in Discovery and Characterization by High-Performance Mass Spectrometry.

Authors:  Mirela Sarbu; Raluca Ica; Alina D Zamfir
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.